ClinicalTrials.gg
Not yet recruitingNCT07723131SCOPE-aSAHUpdated Jul 23, 2026

Structural and Clinical Predictors of Cognitive Impairment After Surgical Treatment for Ruptured Cerebral Aneurysms

An observational study in Subarachnoid Aneurysm Hemorrhage, Microsurgery and Cognitive Impairment, sponsored by University of Campinas, Brazil. Not yet recruiting at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by University of Campinas, Brazil · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
150
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Cognitive Dysfunction with a site in Brazil — 10 open to participants now, 14 under way, 6 of them phase 3. Cognitive Dysfunction · Brazil.

Started
2026
with 4 others
Observational
6 of 40
3 open now
Primary completion
2029-07
later than 10 of 13 live
Registered
39th of 40
by date

Among the 40 studies in Cognitive Dysfunction with a site in Brazil, this one is one of 5 that started in 2026, is one of 6 observational ones, reaches primary completion later than 10 of the 13 other live ones, and was the 39th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

10 of the 40 studies in Cognitive Dysfunction with a site in Brazil are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Cognitive Dysfunction with a site in Brazil, or all of them as a file.
02

Study summary

This study investigates the clinical and structural predictors of long-term cognitive impairment in patients who underwent microsurgical clipping for aneurysmal subarachnoid hemorrhage. Using a retrospective cohort with prospective neuropsychological and MRI assessments, it aims to identify factors associated with late cognitive deficits and improve prognostic stratification, rehabilitation planning, and long-term patient care.

Read the detailed description

Aneurysmal subarachnoid hemorrhage (aSAH) is associated with substantial morbidity, even among patients who remain functionally independent after treatment. Late cognitive deficits, particularly involving memory, attention, and executive function, are common in patients undergoing microsurgical clipping of ruptured cerebral aneurysms; however, the underlying mechanisms remain poorly understood. This study aims to identify clinical, acute radiological, and late structural predictors associated with cognitive impairment in these patients.

Participants will undergo a standardized late postoperative brain magnetic resonance imaging (MRI) evaluation (>1 year after treatment). Structural imaging variables to be analyzed as potential predictors of cognitive impairment include the presence or absence of hippocampal atrophy, frontal lobe atrophy, posterior cerebellar atrophy, pituitary gland atrophy, and deep gray nuclei atrophy, as well as quantitative measurements of white matter hyperintensity volume on FLAIR MRI, residual infarct volume, and cerebral perfusion. These imaging variables will be evaluated in combination with clinical and acute radiological characteristics to identify independent predictors of late cognitive impairment.

03

Conditions studied

  • Subarachnoid Aneurysm Hemorrhage
  • Microsurgery
  • Cognitive Impairment

Keywords

  • Aneurysmal Subarachnoid Hemorrhage
  • Aneurysm Clipping
  • Cognitive Impairment
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients who underwent microsurgical clipping of ruptured cerebral aneurysms following aneurysmal subarachnoid hemorrhage (aSAH), with symptom onset occurring in or after 2020, and who are currently under outpatient follow-up at HC-UNICAMP, will be eligible for inclusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the time of aSAH.
  • Treatment by microsurgical clipping of a ruptured cerebral aneurysm.
  • Survival until study recruitment.
  • Ability to understand and sign .

Exclusion criteria

Exclusion Criteria:

  • Non-aneurysmal subarachnoid hemorrhage.
  • Exclusively endovascular treatment.
  • Previous diagnosis of dementia.
  • Severe neurological or psychiatric disorders unrelated to aSAH with significant cognitive impact.
  • Absolute to MRI.
  • Severe aphasia preventing adequate neuropsychological evaluation.
  • Incomplete clinical data.
  • Inability to attend in-person assessment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Operated <24h

    Patients submited to microsurgical clipping \<24h after aneurysmal subarachnoid hemorrhage

  • Operated 24-72h

    Patients submited to microsurgical clipping between 24h and 72h after aneurysmal subarachnoid hemorrhage

  • Operated >72h

    Patients submited to microsurgical clipping \>72h after aneurysmal subarachnoid hemorrhage

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MoCA) score

    The MoCA is a global cognitive screening test with scores ranging from 0 to 30, where higher scores indicate better cognitive function. Cognitive impairment is defined as a MoCA score \<25, adjusted for educational level. A secondary analysis will also classify participants with MoCA \<23, adjusted for educational level, representing unfavorable functional outcome.

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. EuroQol 5-Dimension 5-Level (EQ-5D-5L)

    The EQ-5D-5L descriptive system generates a health utility index score ranging from less than 0 (health states considered worse than death) to 1.0 (full health), depending on the country-specific value set. Higher scores indicate better health-related quality of life.

    Time frame: Through study completion, an average of 3 years

  2. Hospital Anxiety and Depression Scale (HADS)

    proportion of patients with anxiety or depression. The HADS consists of two subscales: HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D), each ranging from 0 to 21, with higher scores indicating greater symptom severity. The outcome is defined as the proportion of participants with a score ≥8 on either the HADS-A (anxiety) or HADS-D (depression) subscale, consistent with clinically significant symptoms.

    Time frame: Through study completion, an average of 3 years

  3. Modified Rankin Scale (mRS)

    proportion of patients with favorable functional outcome. The Modified Rankin Scale ranges from 0 to 6, where 0 indicates no symptoms, 5 indicates severe disability requiring constant care, and 6 indicates death. Higher scores indicate worse functional outcome. The outcome is defined as the proportion of participants with a favorable functional outcome (mRS 0-2) versus an unfavorable functional outcome (mRS 3-6).

    Time frame: Through study completion, an average of 3 years

  4. Return to work

    proportion of patients returning to work. This outcome is defined as the proportion of participants who returned to paid employment after aneurysmal subarachnoid hemorrhage and microsurgical clipping (yes/no). Among participants who returned to work, the proportion requiring workplace adaptations or modifications (yes/no) will also be assessed.

    Time frame: Through study completion, an average of 3 years

  5. In-hospital complications

    Proportion of participants experiencing in-hospital complications. Each complication will be recorded as a binary outcome (yes/no) during the index hospitalization for aneurysmal subarachnoid hemorrhage. Complications include aneurysm rebleeding, hydrocephalus, need for surgical revision, infection, and delayed cerebral ischemia.

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 site
  • Clinics Hospital - UNICAMP
    Campinas, São Paulo 13083888, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — Yes. De-identified individual participant data will be made available upon reasonable request to the corresponding author, following publication of the primary results, subject to approval of a data access agreement and institutional/ethical requirements.

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2029, 35 months later.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 35 months is below that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 23, 2026
StartEst.
Aug 2026
Primary completionEst.
Jul 2029
CompletionEst.
Dec 2029
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07723131
Collaborators
Hospital de Clinicas da Unicamp - SP
Responsible party
Thiago Magalhaes de Souza (Principal Investigator, University of Campinas, Brazil) — Principal investigator
First posted
Jul 23, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion